ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, is announcing the launch of its highly anticipated LV-2G UNic® Early Access Program. This program marks a significant milestone in lentivirus manufacturing optimization, offering access to groundbreaking vector technology designed to revolutionize viral vector production. With the official launch on March 20, 2024, ProteoNic extends a warm invitation to CDMOs, biotechs, and biopharmaceutical companies to experience firsthand the transformative potential of...